

# Acticor Biotech announces its financial agenda for the 1<sup>st</sup> half of 2023

Paris, France, December 1<sup>st</sup>, 2022 – 6:00 pm CET - Acticor Biotech (Euronext Growth Paris - ISIN : FR00140050J5 – ALACT), a clinical-stage biopharmaceutical company, a spin-off of INSERM, developing an innovative drug for the treatment of cardiovascular emergencies, particularly ischemic strokes, today announces its financial agenda for the 1<sup>st</sup> half of 2023.

Events	Dates*
2022 Full-Year Results	March 29 <sup>th</sup> 2023
Annual General Meeting	May 12 <sup>th</sup> 2023

*\*Information subject to change.*

## About ACTICOR BIOTECH

Acticor Biotech is a clinical stage biopharmaceutical company, a spin-off from INSERM (the French National Institute of Health and Medical Research), which is aiming to develop an innovative treatment for cardiovascular emergencies, including ischemic stroke.

Acticor Biotech is developing glenzocimab (ACT017), a humanized monoclonal antibody (mAb) fragment directed against a novel target of major interest, platelet glycoprotein VI (GPVI). Glenzocimab inhibits platelet binding to the thrombus without affecting physiological hemostasis, thereby limiting the bleeding risk, particularly in the brain.

In May 2022, Acticor Biotech presented positive results from its Phase 1b/2a study, ACTIMIS, at the ESOC, confirming the safety profile and showing a reduction in mortality and intracerebral hemorrhage in the glenzocimab-treated group in patients with stroke. The efficacy of glenzocimab is now being evaluated in an international Phase 2/3 study, ACTISAVE, which will include 1,000 patients. In July 2022, Acticor Biotech was granted "PRIME" status by the European Medicines Agency (EMA) for glenzocimab in the treatment of stroke. This designation will allow the company to strengthen its interactions and obtain early dialogues with regulatory authorities.

Acticor Biotech is supported by a panel of European and international investors (Karista, Go Capital, Newton Biocapital, CMS Medical Venture Investment (HK) Limited, A&B (HK) Limited, Mirae Asset Capital, Anaxago, Primer Capital, Mediolanum farmaceutici and the Armesa foundation). Acticor Biotech is listed on Euronext Growth Paris since November 2021 (ISIN: FR00140050J5 – ALACT).

For more information, visit: [www.acticor-biotech.com](http://www.acticor-biotech.com)

## Contacts

### ACTICOR BIOTECH

Gilles AVENARD, MD  
CEO and Founder

[gilles.avenard@acticor-biotech.com](mailto:gilles.avenard@acticor-biotech.com)

T. : +33 (0)6 76 23 38 13

### NewCap

Mathilde BOHIN / Quentin MASSÉ  
Investor Relations

[acticor@newcap.eu](mailto:acticor@newcap.eu)

T. : +33 (0)1 44 71 94 95

### NewCap

Arthur ROUILLÉ  
Media Relations

[acticor@newcap.eu](mailto:acticor@newcap.eu)

T. : +33 (0)1 44 71 00 15

Sophie BINAY, PhD  
General Manager and CSO  
[Sophie.binay@acticor-biotech.com](mailto:Sophie.binay@acticor-biotech.com)  
T. : +33 (0)6 76 23 38 13